Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review
Por:
Volkmann, J, Albanese, A, Antonini, A, Chaudhuri, KR, Clarke, CE, de Bie, RMA, Deuschl, G, Eggert, K, Houeto, JL, Kulisevsky, J, Nyholm, D, Odin, P, Ostergaard, K, Poewe, W, Pollak, P, Rabey, JM, Rascol, O, Ruzicka, E, Samuel, M, Speelman, H, Sydow, O, Valldeoriola, F, van der Linden, C, Oertel, W
Publicada:
1 nov 2013
Resumen:
Motor complications in Parkinson's disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine.
Filiaciones:
Volkmann, J:
Univ Clin Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany
Albanese, A:
Univ Cattolica Sacro Cuore, Ist Nazl Neurol Carlo Besta, Dipartimento Neurosci Clin, I-20123 Milan, Italy
Antonini, A:
IRCCS San Camillo, Venice, Italy
Chaudhuri, KR:
Kings Coll Hosp London, Dept Neurol, London, England
Clarke, CE:
Univ Birmingham, Sch Med & Dent, Birmingham, W Midlands, England
de Bie, RMA:
Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands
Deuschl, G:
Univ Kiel, Dept Neurol, Kiel, Germany
Eggert, K:
Univ Marburg, Dept Neurol, Marburg, Germany
Houeto, JL:
CHU Poitiers, CIC 802, Serv Neurol, Poitiers, France
Kulisevsky, J:
Univ Autonoma Barcelona, St Pau Hosp, Movement Disorders Unit, Dept Neurol, E-08193 Barcelona, Spain
CIBERNED, Barcelona, Spain
Nyholm, D:
Uppsala Univ, Dept Neurosci, Uppsala, Sweden
Odin, P:
Klinikum Bremerhaven, Dept Neurol, Bremerhaven, Germany
Ostergaard, K:
Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark
Poewe, W:
Med Univ Innsbruck, Dept Clin Neurol, A-6020 Innsbruck, Austria
Pollak, P:
Hop Univ Geneve, Serv Neurol, Geneva, Switzerland
Rabey, JM:
Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Neurol, Zerifin, Israel
Rascol, O:
Univ Hosp, Dept Clin Pharmacol, INSERM, CIC9302, Toulouse, France
Univ Hosp, Dept Neurol, INSERM, CIC9302, Toulouse, France
Univ Hosp, UMR 825, Toulouse, France
Univ Toulouse 3, F-31062 Toulouse, France
Ruzicka, E:
Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic
Samuel, M:
Kings Coll Hosp London, Dept Neurol, London, England
Speelman, H:
Univ Amsterdam, Dept Neurol, Amsterdam, Netherlands
Sydow, O:
Karolinska Univ Hosp, Dept Neurol, Amsterdam, Netherlands
Valldeoriola, F:
Hosp Clin Barcelona, Movement Disorders Unit, Neurol Serv, Barcelona, Spain
van der Linden, C:
AZ Sint Lucas, Dept Neurol, Ghent, Belgium
Oertel, W:
Univ Marburg, Dept Neurol, Marburg, Germany
Hybrid Gold, Green Published
|